Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis (ALS)
A First in Human Study of ORT247 in Healthy Volunteers
This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of…
- Trial name
- NCT06769620
- Testing
- ORT247
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Orthogonal Neuroscience Inc.
Duchenne Muscular Dystrophy, Spinal Muscular Atrophy
Flu Vaccine Study in Neuromuscular Patients 2011
The purpose of the study is to compare the immune response of two different injection methods (Intramuscular V.S. Subcutaneous) of the 2011-2012 seasonal Influenza (Flu) vaccine among patients with neuromuscular conditions who…
- Conditions
- Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Congenital Muscular Dystrophy
- Trial name
- NCT01422200
- Testing
- 2011-2012 seasonal flu vaccine Subcutaneous, 2011-2012 seasonal flu vaccine Intramuscular
- Volunteers
- 22 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Spinal Muscular Atrophy
Spinal Muscular Atrophy Neonatal Screening Program
Spinal muscular atrophy (SMA) is a group of disorders caused by the degeneration of the motor neuron cells of the anterior horn of the spinal cord and, in some subtypes, of the bulbar motor neurons.
- Trial name
- NCT06310421
- Testing
- Screening SMA test
- Where
- 2 sites in Italy
- Volunteers
- 11,500 people
- Sponsor
- IRCCS Burlo Garofolo
Muscular Atrophy, Spinal
Pilot Study of Growth Hormon to Treat SMA Typ II and III
The purpose of this study is to determine whether Growth hormon can increase strength in spinal muscular atrophy type II and III.
- Trial name
- NCT00533221
- Testing
- somatotropin
- Where
- 6 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Freiburg
Disorder of Consciousness, Paralysis
Awareness Detection and Communication in Disorders of Consciousness
STUDY OVERVIEW Brain injury can result in a loss of consciousness or awareness, to varying degrees. Some injuries are mild and cause relatively minor changes in consciousness.
- Conditions
- Disorder of Consciousness, Paralysis, Motor Neuron Disease, Stroke
- Trial name
- NCT03827187
- Testing
- Motor imagery based EEG-BCI
- Where
- 18 sites in Ireland, United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Ulster
Amyotrophic Lateral Sclerosis
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS.
- Trial name
- NCT04882904
- Testing
- Actimyo°
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Muscular Atrophy, Spinal
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
In this study, researchers will know more about the effects of nusinersen, also known as Spinraza®, in pregnant participants with spinal muscular atrophy, also known as SMA.
- Trial name
- NCT05789758
- Testing
- No Intervention
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis (ALS)
HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial
Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality.
- Trial name
- tDCS-ALS (NCT06719947)
- Testing
- Active HD-tDCS, Simulated HD-tDCS
- Where
- 4 sites in Brazil, Chile
- Volunteers
- 80 people
- Sponsor
- Universidade Federal do Rio Grande do Norte
Amyotrophic Lateral Sclerosis
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients.
- Trial name
- NCT00035815
- Testing
- Insulin like growth factor, type 1
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 330 people
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS
This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral…
- Trial name
- TUDCA-ALS (NCT03800524)
- Testing
- Tauroursodeoxycholic Acid
- Where
- 25 sites in Belgium, France and 5 more
- Volunteers
- 337 people
- Sponsor
- Humanitas Mirasole SpA
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Tetraplegia
NeuroCognitive Communicator: Safety Study
Individuals suffering from tetraplegia as a result of cervical spinal cord injury, brainstem stroke, or amyotrophic lateral sclerosis (ALS) cannot independently perform tasks of daily living.
- Trial name
- NCC-1701 (NCT03100110)
- Testing
- NeuroCognitive Communicator
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Ottawa Hospital Research Institute
Amyotrophic Lateral Sclerosis
Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders
The purpose of this study is to collect CSF and blood samples that can be used in future research studies to identify potential biomarkers in blood and cerebrospinal fluid (CSF) collected in Amyotrophic Lateral Sclerosis (ALS)…
- Trial name
- NCT05116943
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Spinal Muscular Atrophy
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in individuals with SMA who are between the ages…
- Trial name
- SOLAR (NCT07444476)
- Testing
- Salanersen
- Where
- 3 sites in United States, China
- Volunteers
- 90 people
- Sponsor
- Biogen
Spinal Muscular Atrophy (SMA)
Service Evaluation for Newborn Screening for Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is a disease that causes progressive muscle weakness. There are many types- the most severe and most common, type 1, affects very young babies, and is life-threatening if untreated.
- Trial name
- SENS (NCT07888868)
- Where
- 3 sites in United Kingdom
- Volunteers
- 750,000 people
- Sponsor
- University of Oxford
Spinal Muscular Atrophy, Spine Deformity
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA).
- Conditions
- Spinal Muscular Atrophy, Spine Deformity, Scoliosis
- Trial name
- PIERRE (NCT05866419)
- Testing
- ThecaFlex DRx System
- Where
- 21 sites in United States, Germany and 3 more
- Volunteers
- 90 people
- Sponsor
- Alcyone Therapeutics, Inc
Amyotrophic Lateral Sclerosis
FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS
The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS.
- Trial name
- FUNCtion ALS (NCT07674667)
- Testing
- TRCN-1023
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Trace Neuroscience, Inc.
Amyotrophic Lateral Sclerosis, Myasthenia Gravis
Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis
The aim of this study is to understand how well a 6-week virtual yogic breathing exercise program (YBEP) will improve breathing, speech, and emotional well-being in people with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT05979688
- Testing
- yogic breathing exercise
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Alabama at Birmingham
Amyotrophic Lateral Sclerosis
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system.
- Trial name
- GALS (NCT01854294)
- Testing
- GM604
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Amyotrophic Lateral Sclerosis
Geometrical Facial Deformation According to Posture in Amyotrophic Lateral Sclerosis
The measurement of the facial deformation according to the body posture will be conducted by 3D scanning for each posture after marking the landmarks on the face.
- Trial name
- NCT04798183
- Testing
- 3-dimensional scan
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pusan National University Yangsan Hospital
Amyotrophic Lateral Sclerosis
Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients
The purpose of the study is to test whether noninvasive positive pressure ventilation (NIPPV) without expiratory positive airway pressure (EPAP) (inspiratory positive airway pressure (IPAP)-only) will result in an increase in…
- Trial name
- NCT01154283
- Testing
- Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Kirsten Gruis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.